Effect of Geteng Tongluo Capsule Combined with Fluoxetine on Inflammatory Factors and Neurotransmitters in Patients with Post-stroke Dementia

Abstract

Objective To explore the effect of Getong Tongluo capsules combined with fluoxetine on inflammatory factors and neurotransmitters in patients with post-stroke depression (PSD). Methods 112 patients with PSD who were treated in our hospital from January 2019 to October 2021 were randomly divided into a control group and an observation group, with 56 cases in each group. Patients in both groups were given conventional treatment with Western medicine, based on which fluoxetine was given to the control group, while the observation group was treated with Getong Tongluo capsules on the basis of the control group. Clinical efficacy, inflammatory factor levels, neurotransmitter levels, and national institutes of health stroke scale (NIHSS) and Hamilton depression scale (HAMD) scores were compared between the two groups. Results The total effective rate of the observation group was markedly higher than that of the control group (P<0.05). After treatment, the levels of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), S100-β protein and NIHSS and HAMD scores were significantly lower than those before treatment (P<0.05), and those of the observation group were significantly lower than those of the control group (P<0.05). After treatment, the levels of nerve growth factor (NGF) and dopamine (DA) in the two groups were significantly higher than those before treatment (P<0.05), and those of the observation group were significantly higher than those of the control group (P<0.05). Conclusion The combination of Getong Tongluo capsules combined with fluoxetine can effectively alleviate the clinical symptoms of PSD patients, reduce the inflammatory response, regulates neurotransmitters NGF, DA, and S100-β levels, and alleviate the depression of patients.